Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
نویسندگان
چکیده
Background. Immune thrombocytopenia (ITP), or idiopathic thrombocytopenic purpura, is a hematological autoimmune disease characterized by bleeding and an isolated decrease in platelet count <100 × 10 9 / l. The decision to start treatment for ITP depends on several factors. strategy based the clinical symptoms, with focus reducing risk of severe increasing counts. Aim. To evaluate efficacy 2 nd line therapy thrombopoietin receptor agonist eltrombopag patients ITP. Materials methods. 490 are under observation at center orphan diseases M. F. Vladimirskiy Moscow Regional Research Clinical Institute. present study included 186 primary after 1 st glucocorticosteroid therapy. eltrombopag, agonist, was prescribed as Results. median prior all 27.5 therapy, significant (by %) increase levels (median 135 l) complete response according recommendations were noted. Conclusion. Glucocorticosteroids (prednisolone, dexamethasone) remain drugs choice Treatment this group most cases allows achieving optimal level preventing bleeding. In case inefficiency, intolerance, occurrence side effects, appointment agonists romiplostim recommended. dose 50 mg daily weeks has been able achieve levels, correct hemorrhagic syndrome, reduce number effects during first-line improve patient’s quality life.
منابع مشابه
Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag
Chronic immune thrombocytopenia (ITP) is an autoimmune disease that results in chronically low platelet counts. Treatment guidelines recommend a platelet count of at least 50,000/µl before minor surgery and at least 80,000/µl before major surgery. This retrospective analysis explored invasive non-dental procedures associated with the risk of bleeding (hemostatic challenges) among patients with ...
متن کاملmodern surgical techniques in treatment of patients with cleft lip & cleft palate
چکیده ندارد.
15 صفحه اولthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
BACKGROUND Eltrombopag is a thrombopoietin receptor agonist with excellent treatment outcomes in immune thrombocytopenia (ITP). Here, we analyzed the dose of eltrombopag required to achieve and maintain safe platelet counts in Korean ITP patients. METHODS Adult refractory ITP patients (<30,000 platelets/µL) were enrolled. Eltrombopag doses were increased to achieve a target platelet count (≥5...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ???????????????
سال: 2023
ISSN: ['0235-2435']
DOI: https://doi.org/10.17650/1818-8346-2023-18-3-65-69